Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 481-486

  Chen, Xinyue ^a   Cao, Zhenhuan ^a   Liu, Yali ^a   Zhang, Hongwei ^a   Zhang, Yonghong ^a   Ma, Lina ^a   Jin, Yi ^a   Yu, Haibin ^a   Ma, Bing ^a   Zheng, Yanhong ^a   Wu, Hao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Combination treatment; Hepatitis B surface antigen seroconversion

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT RESPONSE;

EID: 84863115236     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06970.x     Document Type: Article

References (15)

1. Chinese Liver Disease Association and Infectious Diseases of Chinese Medical Association Branch. Guideline of chronic hepatitis B in China. Chin. J. Intern. Med. 2011; 50: 2-19.
2. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 2009; 29 (Suppl. 1): 1-8.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
4. Buster E, Flink H, Cakaloglu Y etal. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
5. Yuen M, Wong D, Fung J etal. HbsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
6. Zonneveld M, Honkoop P, Hansen B etal. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
8. Lau GK, Piratvisuth T, Luo KX etal. Peg-interferon Alfa 2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-95.
9. Marcellin P, Lau GK, Bonino F etal. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-17.
10. Marcellin P, Bonino F, Lau GK etal. Sustained response of hepatitis B e antigen-negative patients 3years after treatment with peginterferon a-2a. Gastroenterology 2009; 136: 1618-28.
11. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49: S103-S111.
12. Liu J, Yang HI, Lee MH etal. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-82.
13. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 5: 1187-92.
14. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-55.
15. Janssen HL, Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.